- Home
- TLSI vs CBUS Comparison
TLSI vs CBUS Comparison
Compare TLSI & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- CBUS
- Stock Information
- Founded
- TLSI 2010
- CBUS 2010
- Country
- TLSI United States
- CBUS United States
- Employees
- TLSI N/A
- CBUS N/A
- Industry
- TLSI Medical Specialities
- CBUS Agricultural Chemicals
- Sector
- TLSI Health Care
- CBUS Industrials
- Exchange
- TLSI Nasdaq
- CBUS Nasdaq
- Market Cap
- TLSI 166.8M
- CBUS 160.8M
- IPO Year
- TLSI N/A
- CBUS 2017
- Fundamental
- Price
- TLSI $4.98
- CBUS $4.60
- Analyst Decision
- TLSI Strong Buy
- CBUS Strong Buy
- Analyst Count
- TLSI 2
- CBUS 3
- Target Price
- TLSI $14.00
- CBUS $23.67
- AVG Volume (30 Days)
- TLSI 66.5K
- CBUS 134.9K
- Earning Date
- TLSI 08-14-2024
- CBUS 08-08-2024
- Dividend Yield
- TLSI N/A
- CBUS N/A
- EPS Growth
- TLSI N/A
- CBUS N/A
- EPS
- TLSI N/A
- CBUS N/A
- Revenue
- TLSI $24,736,000.00
- CBUS $2,961,000.00
- Revenue This Year
- TLSI $61.24
- CBUS $28.62
- Revenue Next Year
- TLSI $47.32
- CBUS $286.56
- P/E Ratio
- TLSI N/A
- CBUS N/A
- Revenue Growth
- TLSI 67.75
- CBUS 816.72
- 52 Week Low
- TLSI $3.32
- CBUS $4.26
- 52 Week High
- TLSI $10.42
- CBUS $23.18
- Technical
- Relative Strength Index (RSI)
- TLSI 37.92
- CBUS 23.41
- Support Level
- TLSI $4.80
- CBUS $4.26
- Resistance Level
- TLSI $5.47
- CBUS $7.49
- Average True Range (ATR)
- TLSI 0.35
- CBUS 0.67
- MACD
- TLSI -0.04
- CBUS -0.23
- Stochastic Oscillator
- TLSI 15.14
- CBUS 9.14
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.